Avoid common mistakes on your manuscript.
Correction: Oncol Ther https://doi.org/10.1007/s40487-023-00251-6
In this article the authors erroneously mentioned the drug repotrectinib in the introduction of the paper. This should be replaced with the drug entrectinib.
The original article has been corrected.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/.
About this article
Cite this article
Metro, G., Gariazzo, E., Costabile, S. et al. Correction: Repotrectinib’s Clinical Benefit and Its Brain Penetration in a Patient with Meningeal Carcinomatosis from G2032R-Mutated ROS-1 Positive Non-Small Cell Lung Cancer. Oncol Ther 12, 173–174 (2024). https://doi.org/10.1007/s40487-023-00258-z
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40487-023-00258-z